EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2 www.in-academy.uz/index.php/ejmns

ANALYSIS OF MEASURES FOR ACCURATE DIAGNOSIS OF VIRAL HEPATITIS AT AN EARLY STAGE AND THE NEED FOR THEIR IMPROVEMENT

Dilafruz Sh. Gulmurotova[1]
Abror SH. Shamuratov[2]
Ibroxim Sh. Shavkatov[3]
Farrux A. Abdiqodirov[4]
[1]Assistant at the Department of Microbiology, virology and immunology of Tashkent State Medical University, Tashkent, Uzbekistan, E-mail: dilafruzgulmurotova82@gmail.com
[2]Assistant at the Department of Microbiology, virology and immunology of Tashkent State Medical University, Tashkent, Uzbekistan, E-mail: Abror7300@mail.ru
[3]Student of Tashkent State Medical University, 2nd Faculty of General Medicine, Group 214A, Tashkent, Uzbekistan, E-mail: ibroximshavkatov17102006@gmail.com
[4]Student of Tashkent State Medical University, 2nd Faculty of General Medicine, Group 214A, Tashkent, Uzbekistan, E-mail: abduqodirovfarrux968gmail.com
https://doi.org/10.5281/zenodo.17589113

ARTICLE INFO

Received: 06th November 2025
Accepted: 11th November 2025
Online: 12th November 2025

KEYWORDS

Cirrhosis direct antiviral medications, Hepatocellular carcinoma, Hepatitis A, Hepatitis B, Hepatic C Hepatitis D, Hepatitis E.

ABSTRACT

Due to its high rates of morbidity and mortality, hepatitis remains a serious worldwide health concern. Early prediction of hepatitis outcomes is still a crucial area for development, despite advancements in diagnosis and therapy. By using a variety of cutting-edge machine learning (ML) algorithms to predict hepatitis, this study aims to close this gap and support international initiatives to improve public health outcomes. The hepatitis dataset from the UCI repository, which comprises 155 people and 20 characteristics pertaining to clinical information, test results, and demographics, was used in the study. Despite advancements in antiviral medication and effective vaccinations, viral hepatitis continues to have a significant global burden. Hepatitis A, B, C, D, and E are the five types of hepatitis viruses. Along with HIV infection, malaria, and tuberculosis, hepatitis B and hepatitis C virus infections rank among the top four infectious diseases in the world in terms of mortality. About 47% of such deaths can be attributed to the hepatitis B virus, 48% to the hepatitis C virus, and the remaining portion to the hepatitis A and hepatitis E viruses. With the technologies and strategies already in use, hepatitis

epidemics can be stopped as a serious threat to public health. It is possible to avoid viral hepatitis A, B, and E infections with effective vaccinations. Over 90% of people with chronic hepatitis C can be cured with new oral, well-tolerated therapy regimens. People with chronic hepatitis B virus infection can also receive effective therapy; however, for the majority of patients, this treatment must be long-term, and more recent advancements hope to provide a "functional cure" for hepatitis B. The latest recent developments in viral hepatitis diagnosis and therapy are covered in this review article.

Introduction. Despite significant advancements in prevention and treatment in recent years, viral hepatitis still has a significant global burden. In 2015, 1.34 million people died from viral hepatitis, which is comparable to mortality from HIV, malaria, and tuberculosis. The majority of viral hepatitis cases are caused by five liver-specific (hepatotropic) viruses. These are the viruses that cause hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E (HEV). Of these, 96% of viral hepatitis deaths are caused by HBV and HCV. Hepatocellular carcinoma (HCC) and cirrhosis are the two most common liver problems. According to reports, there were an estimated 257 million chronic HBV infections and 71 million chronic HCV infections in 2015. The World Health Organization (WHO) pledged in 2016 to eradicate viral hepatitis as a threat to public health by 2030, which is defined as a 90% decrease in incidence and a 65% decrease in mortality as compared to the 2015 baseline [1,2,3]. However, the majority of patients lack a diagnosis, and access to treatment is restricted, making the goal difficult to achieve. The five viruses differ significantly in terms of epidemiology, risk for chronicity, risk for liver consequences, and therapies. All five viruses can cause acute infection, but HBV, HCV, and HDV are the most common causes of chronic illness. This review offers an overview of recent developments in the diagnosis and treatment of viral hepatitis, with particular attention to rapid diagnostic techniques, newly developed treatments that are presently undergoing clinical trial testing, the creation of vaccines to treat chronic hepatitis B (CHB), and the use of vaccines to prevent HEV in certain regions of the world. Improving patient outcomes requires early hepatitis diagnosis. Hepatocellular carcinoma (HCC) survival rates can be greatly increased by early discovery and treatment, according to studies. However, complex clinical data, such as missing information, intricate linkages between data points, and imbalance in the classes of disorders being evaluated, frequently causes problems for traditional techniques of identifying health issues [4,5,6,7]. Because machine learning (ML) models have demonstrated promising results in disease prediction, successfully identifying conditions like diabetic retinopathy and axial spondylarthritis using complex clinical metrics and imaging data, medical professionals are choosing ML to improve diagnostic accuracy and manage large patient data. Due to the complexity and diversity of patient data, it is still

challenging to diagnose hepatitis in its early stages and predict patient outcomes, despite advancements in treatment. Data-driven tools that can reliably identify risk variables and forecast disease outcomes by selecting the best approach are desperately needed to support clinical decision-making. Additionally, a major drawback of existing methods is their concentration on particular clinical and demographic categories, which frequently ignores the entire spectrum of hepatitis patients [8,9]. Numerous research focus on a few machine learning algorithms or use clinical survey data from certain demographics. Hepatitis can be diagnosed more accurately, inclusively, and promptly by addressing the existing constraints through a thorough and comparative review of machine learning techniques. This helps achieve SDG 3.8, which promotes improved access to cutting-edge diagnostic tools and universal health care. To further address typical concerns about overfitting in small datasets, our work performs several iterations of tenfold cross-validation with different random seeds to guarantee the stability and reproducibility of our findings. We also specifically take into account practical issues that have not been given much attention in previous hepatitis prediction literature, such as gender-specific survival patterns and class imbalance. In order to improve health outcomes and lower death rates worldwide, this groundbreaking study attempts to pinpoint the primary causes of hepatitis and offer practical, data-driven insights for focused therapies [10,11,12,13].

The main purpose of the presented peer-reviewed manuscript is a brief analysis of measures for the accurate diagnosis of viral hepatitis at an early stage and the need for their improvement.

Diagnostic analysis. Viral excretion into the stool through the biliary tree peaks around the time of maximal liver enzyme increases, and HAV viremia starts before sickness. At or soon after an increase in ALT, anti-HAV antibodies are found. Anti-HAV IgM isotype antibodies are first found, and after six months of infection, they usually drop below detection limits. Anti-HAV IgG is found before IgM levels decline. Anti-HAV IgG is long-lasting and protective. Both IgG and IgM isotypes can be identified by measuring "total" anti-HAV antibodies, which, if present, provide lifetime protection against reinfection. Acute and chronic infections cannot be distinguished by total antibodies. Testing for IgM-specific antibodies is necessary; if the results are positive, an acute infection is diagnosed. There is no clinical reason for identifying the virus using either antigen or RNA detection techniques because HAV is an acute self-limited disease and IgM antibodies are present both before and during infection. Consequently, there are no commercially accessible NAT or HAV antigen detection assays [17-23].

Accurate diagnosis of acute hepatitis. Traditionally, an infection has been identified by using enzyme immunoassay (EIA) to identify serum immunoglobulin M (IgM) anti-HAV antibodies. However, point of care (POC) testing has gained popularity because EIA testing is time-consuming and infrastructure-intensive. In addition to giving people in resource-poor places a way to receive a diagnosis, faster diagnostic testing may make it easier to identify susceptible individuals during outbreaks. A commercial fast immunochromatographic test for HAV IgM achieved 81% sensitivity and 100% specificity, according to a Brazilian study. The effectiveness of a quick salivary test for

HAV IgG with sensitivity comparable to human plasma analysis was shown in another trial with 5,438 individuals in Puerto Rico [1-6].

AI in viral hepatitis early detection and diagnosis. AI's sophisticated image analysis, digital pathology, and machine learning algorithms have greatly enhanced the early identification of viral hepatitis. AI-driven image analysis in radiology is one of the most significant uses. In patients with viral hepatitis, deep learning models can evaluate medical imaging modalities like computed tomography (CT), magnetic resonance imaging, and ultrasound to identify cirrhosis, liver fibrosis, and HCC. AI systems have outperformed conventional radiological evaluations in detecting HCV-related liver lesions from CT scans. Mueller matrix polarimetry and other cutting-edge AI-driven optical imaging methods have shown excellent diagnostic accuracy in identifying HBV. By using AI and optical biomarkers for early-stage viral identification, our method enhances conventional radiology and pathology [7-12]. Furthermore, automated fibrosis staging with AI-powered elastography has reduced the need for liver biopsies, offering a quick and non-invasive method of diagnosis. The histological assessment of liver specimens has been improved by the combination of AI with digital pathology. AI-based image analysis methods are as accurate as skilled pathologists at identifying liver damage caused by HBV and HCV. In order to help with diagnosis and prognosis assessment, deep learning models trained on extensive datasets of histological slides can evaluate necroinflammation, fibrosis progression, and even early-stage carcinogenesis. Beyond pathology and imaging, machine learning algorithms are essential for detecting high-risk individuals and forecasting the course of diseases. A machine-learning integrated model integrates clinical parameters (Alanine aminotransferase, HBV DNA, Fibroscan values) and immunological indicators (NKbright cell surface molecule expression, CD3+ T cell activity) for the screening of HBV patients for antiviral treatment [13-16]. According to the model, 10.8% of "non-treatment-eligible" patients required intervention during follow-up, which reduced the likelihood that liver disease would worsen if treatment was postponed. Early intervention is made possible by supervised learning models like Support Vector Machines (SVM) and K-Nearest Neighbor (KNN), which have shown great accuracy in categorizing patients based on liver function test results. While unsupervised methods, like clustering, find latent patterns in unannotated data, supervised learning models, like SVM and KNN, rely on labeled datasets for classification. Additionally, sophisticated deep learning techniques, including as C5.0 algorithms and hybrid quantum neural networks, have decreased diagnostic delays by increasing the accuracy of HCV categorization. An emerging paradigm that combines the concepts of quantum computing and traditional deep learning is hybrid quantum neural networks [17-21].

Creation of a model based on machine learning. The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) reporting guideline statement checklist for prediction model construction was followed in the conduct of this investigation. The mean and standard deviation were used to summarize continuous variables prior to the machine learning study, whilst percentages and numbers (proportions) were used to summarize categorical variables. The caret package25 was used to conduct the machine learning study in R v3.5. A stratified train-

test split (70% training and 30% testing) was used to separate the data set. A stratified train-test split (70% training and 30% testing) was used to separate the data set [6-11]. The investigation used ten-fold cross validation to assess the predictive model's performance. Recursive partitioning ("trees") and SVM, two machine learning techniques, were applied in tandem as classification algorithms to patient data that included regular clinical chemistry and haematology results (predictor variables) and HBsAg results (response variable). The predictor variable patterns and thresholds that distinguish HBsAg immunoassay positive from negative results were determined using these supervised learning methods. The patient data was subjected to random forest algorithms, which ordered the predictor variables (routine chemistry and haematology indicators) according to significance for categorization as HBsAg positive or negative. Using various hyper-parameter values, ten-fold cross-validation was carried out ten times. Using tuneLength, we optimized the sigma for SVM, the mtry parameter for random forests, and the complexity parameter for decision trees. The hyper-parameter optimization was done using the R package caret. A confusion matrix was utilized to evaluate the predictions made using the best model on the test data with the actual results. The suggested performance metrics for classification tasks—accuracy, sensitivity, specificity, precision, F1, and AUC—were used to assess the prediction model [16-22].

Discussion. Hepatocellular carcinoma, cirrhosis, and liver fibrosis are all consequences of viral hepatitis, which includes hepatitis B and hepatitis C (HCV). Despite their effectiveness, traditional diagnostic techniques can have issues with timeliness, accuracy, and accessibility. The detection, diagnosis, and treatment of viral hepatitis have all been improved by artificial intelligence (AI), which has become a game-changing technology in the medical field. With an emphasis on early detection through image analysis, digital pathology, and machine learning algorithms, this paper investigates the role of AI in the management of viral hepatitis. Convolutional neural networks and other AI-driven image processing methods have shown great accuracy in identifying liver lesions associated with HCV using computed tomography scans. Early risk categorization is further improved by supervised learning models like hybrid quantum neural networks and support vector machines. By predicting treatment responses, speeding up drug discovery, and developing precision medicine, AI also makes individualized treatment easier [5,6,7,10]. Additionally, by monitoring treatment compliance and forecasting the spread of disease, AI supports epidemiological surveillance. Despite its potential, issues like algorithmic bias, data privacy, and regulatory compliance need to be resolved to guarantee the fair and efficient application of AI. Expanding AI applications in low-resource environments and incorporating AI into clinical operations are future prospects. AI-assisted diagnosis and treatment could transform the treatment of viral hepatitis, enhancing patient outcomes and lowering the incidence of the illness worldwide. Pandemics and endemics of viral hepatitis have a severe negative impact on people's lives, communities, and healthcare systems. Another rising cause of death for HIV-positive individuals is viral hepatitis. The five hepatitis viruses—A, B, C, D, and E—have distinct routes of transmission, impact distinct groups, and produce disparate health effects. In

addition to providing customized interventions for each virus, an effective response necessitates a variety of standard measures for prevention, diagnosis, treatment, surveillance, and screening. Treatment for acute hepatitis A infection is usually supportive and necessitates early identification. Usually, acute hepatitis B and C goes untreated until it develops into a chronic illness [2,9,11,14]. Pregnant individuals are particularly susceptible to acute hepatitis E, which can result in a high death rate. Because HBV and HCV infections produce chronic, lifelong infections that cause permanent liver damage that results in cirrhosis and, in certain circumstances, HCC, they account for the majority of hepatitis-associated morbidity (96%) and mortality (91%) worldwide. Although there are still some small issues, hepatitis C treatment represents the greatest advancement in viral hepatitis in recent decades. On the other hand, despite recent progress in our understanding of HBV, there are still major challenges because of its integration with the host DNA. The first hepatitis D drug approved in the EU is encouraging. Scientific developments in HBV virology and immunology are crucial for achieving a functional cure for CHB patients in the upcoming ten years. All things considered, significantly more funding and new developments are required to make these treatments broadly accessible if the hepatitis elimination goals are to be met by 2030. A national elimination plan and adequate funding are required to enable region-specific solutions that take into account local epidemiology and disease load [18-21].

Conclusions. Sustainable Development Goal (SDG) 3.3, which aims to combat hepatitis and improve the management of communicable diseases, is in line with the integration of machine learning techniques to predict survival outcomes in hepatitis patients, which is crucial to the advancement of healthcare systems. In order to assess the predictive ability of ML algorithms for hepatitis prediction, this study presents a novel multi-model comparison methodology that uses rigorous cross-validation and Boruta-based feature selection. Random Forest outperformed the other models in the majority of parameters, which makes it especially well-suited for clinical applications that demand high recall and accuracy. But the dataset's gender disparity and poor specificity point to areas that need more research.

Furthermore, using real-world clinical data and extending feature selection methods beyond Boruta, like SHAP or Recursive Feature Elimination, may improve these models' performance and interpretability. All things considered, our results not only highlight the promise of machine learning in hepatitis prediction but also offer a reliable, repeatable process for developing predictive healthcare tools. In areas with limited resources, when early diagnosis is essential to improving patient outcomes, this concept is very helpful.

References:

1. Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res. 2021 Jun;14(3):139-156. doi: 10.14740/gr1405.

2. Khatun, P., Umam, S., Razzak, R.B. et al. A study on the effectiveness of machine learning models for hepatitis prediction. Sci Rep 15, 30659 (2025). https://doi.org/10.1038/s41598-025-07104-4
3. Syafaah, L., Zulfatman, Z., Pakaya, I. & Lestandy, M. Comparison of machine learning classification methods in hepatitis C virus. J. Online Inf. 6, 73. https://doi.org/10.15575/join.v6i1.719 (2021).
4. Edeh, M. O. et al. Artificial intelligence-based ensemble learning model for prediction of hepatitis C disease. Front Public Health 10, 892371. https://doi.org/10.3389/fpubh.2022.892371 (2022).
5. Mamdouh Farghaly, H., Shams, M. Y. & Abd El-Hafeez, T. Hepatitis C virus prediction based on machine learning framework: A real-world case study in Egypt. Knowl. Inf. Syst. 65, 2595–2617. https://doi.org/10.1007/s10115-023-01851-4 (2023).
6. Ma, L.-L., Yang, Y., Ge, X., Wan, Y. & Sang, X. Prediction of disease progression of chronic hepatitis C based on XGBoost algorithm. In 2020 International Conference on Robots & Intelligent System (ICRIS) 598–601 (2020).
7. Evon, D. M. et al. Fatigue in patients with chronic hepatitis B living in North America: Results from the hepatitis B research network (HBRN). Dig. Dis. Sci. 61, 1186–1196. https://doi.org/10.1007/s10620-015-4006-0 (2016).
8. Ahmed, I., Mohammed, D. & Zidan, K. Diagnosis of hepatitis disease using machine learning techniques. Indonesian J. Electr. Eng. Comput. Sci. 26, 1564. https://doi.org/10.11591/ijeecs.v26.i3.pp1564-1572 (2022).
9. de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health 8, e180–e190. https://doi.org/10.1016/s2214-109x(19)30488-7 (2020).
10. Xiahou, X. & Harada, Y. Customer churn prediction using AdaBoost classifier and BP neural network techniques in the E-commerce industry. Am. J. Ind. Bus. Manag. 12, 277–293. https://doi.org/10.4236/ajibm.2022.123015 (2022).
11. Sharma, V., Yadav, S. & Gupta, M. Heart Disease Prediction Using Machine Learning Techniques 177–181. https://doi.org/10.1109/icacccn51052.2020.9362842 (2020).
12. Sharma, V., Yadav, S. & Gupta, M. Heart Disease Prediction Using Machine Learning Techniques 177–181. https://doi.org/10.1109/icacccn51052.2020.9362842 (2020).
13. Christanto, H. et al. Analisis perbandingan decision tree, support vector machine, Dan Xgboost Dalam Mengklasifikasi review hotel trip advisor. Jurnal Teknologi Informatika Dan Komputer 9, 306–319. https://doi.org/10.37012/jtik.v9i1.1429 (2023).
14. Mijwil, M., Salem, I. & Abttan, R. Utilisation of machine learning techniques in testing and training of different medical datasets. Asian J. Comput. Inf. Syst. 9, 29–34. https://doi.org/10.24203/ajcis.v9i4.6765 (2021).
15. Bansal, M., Goyal, A. & Choudhary, A. A comparative analysis of K-nearest neighbor, genetic, support vector machine, decision tree, and long short term memory algorithms in machine learning. Decis. Analyt. J. 3, 100071. https://doi.org/10.1016/j.dajour.2022.100071 (2022).

16. Elkenawy, E.-S.M., Alhussan, A. A., Khafaga, D. S., Tarek, Z. & Elshewey, A. M. Greylag goose optimization and multilayer perceptron for enhancing lung cancer classification. Sci. Rep. 14, 23784. https://doi.org/10.1038/s41598-024-72013-x (2024).
17. Alzakari, S. A., Alhussan, A. A., Qenawy, A.-S.T. & Elshewey, A. M. Early detection of potato disease using an enhanced convolutional neural network-long short-term memory deep learning model. Potato Res. 68, 695–713. https://doi.org/10.1007/s11540-024-09760-x (2025).
18. Alfyani, R. & Muljono. In 2020 International Seminar on Application for Technology of Information and Communication (iSemantic) 196–201.
19. Elshewey, A. M. et al. Optimizing HCV disease prediction in Egypt: The hyOPTGB framework. Diagnostics 13, 3439 (2023).
20. Nivaan, G. V. & Emanuel, A. W. R. Analytic predictive of hepatitis using the regression logic algorithm. In 2020 3rd International Seminar on Research of Information Technology and Intelligent Systems (ISRITI) 106–110 (2020).
21. Chen ML, Li WM, Liu Q, Gu Y, Wang JR. Revolutionizing viral hepatitis management: Artificial intelligence-assisted diagnosis and personalized treatment. Artif Intell Gastroenterol 2025; 6(1): 107277 [DOI: 10.35712/aig.v6.i1.107277]
22. Ajuwon, B.I., Richardson, A., Roper, K. et al. The development of a machine learning algorithm for early detection of viral hepatitis B infection in Nigerian patients. Sci Rep 13, 3244 (2023). https://doi.org/10.1038/s41598-023-30440-2
23. Prasidthrathsint K, Stapleton JT. Laboratory Diagnosis and Monitoring of Viral Hepatitis. Gastroenterol Clin North Am. 2019 Jun;48(2):259-279. doi: 10.1016/j.gtc.2019.02.007.